Bempegaldesleukin plus Nivolumab in First-line Metastatic Urothelial Carcinoma: Results from PIVOT-02
Arlene O. Siefker‐Radtke, Daniel C. Cho, Adi Diab, Mario Sznol, Mehmet Asım Bilen, Arjun Vasant Balar, Giovanni Grignani, Erika Puente-Poushnejad, Lily Tang, David Chien, Ute Hoch, Arkopal Choudhury, Danni Yu, Sue Currie, Mary Tagliaferri, Jonathan Zalevsky, Michael E. Hurwitz, Nizar M. Tannir
Topics & Concepts
MedicineMetastatic Urothelial CarcinomaNivolumabInternal medicineOncologyResponse Evaluation Criteria in Solid TumorsAdverse effectBiomarkerProgression-free survivalConfidence intervalProgressive diseasePhases of clinical researchUnivariate analysisChemotherapyGastroenterologyImmunotherapyUrologyBladder cancerCancerUrothelial carcinomaMultivariate analysisChemistryBiochemistryBladder and Urothelial Cancer TreatmentsCancer Immunotherapy and BiomarkersFerroptosis and cancer prognosis